Abstract:
A fluorine-containing copolymer, containing: chlorotrifluoroethylene monomer units (A); and monomer units (B), which are obtained by polymerizing a monomer selected from the group consisting of (i) a monomer having a formula: CH2═CHCOON(R0)2, wherein each R0 is independently a hydrogen or an alkyl group; (ii) N-vinylcaprolactam; (iii) a monomer having a formula: CH2═CR1CH2OCH2CR2═CH2, wherein R1 and R2 are each independently a hydrogen, a fluorine, or a methyl group; (iv) a monomer having a formula: CH2═CHCH2CH(CH3)—R3, wherein R3 is a linear alkyl group comprising 1 to 7 carbons; and (v) a monomer of methyl 2-fluoroacrylate, wherein a ratio, (A)/((A)+(B)), is from 3 to 99 mol %, a fluorine content of the copolymer is from 15 to 75 mol %, and a molecular weight of the copolymer is from 1,000 to 1,000,000.
Abstract:
A method for radiating a heat of illumination for growing plant includes: detecting an external temperature and an internal temperature of a plant growth chamber, and when the external temperature is higher than the internal temperature, executing a first heat radiation in which a cold air generated from a cooling system of a building is introduced into a ventilation/air-conditioning duct to which a rear side of the lights is exposed. The method further includes, when the internal temperature is higher than the external temperature, executing a second heat radiation mode in which an external cold air is introduced into the ventilation/air-conditioning duct.
Abstract:
The present invention relates to N-Substituted thiomorpholine compounds of formula I, the possible isomers, the pharmaceutically acceptable salts, the solvates, the hydrates or the prodrugs thereof as inhibitors of dipeptidyl peptidase IV (DPP-IV); and to a method for preparing the compounds of formula I, pharmaceutical compositions comprising the compounds of formula I and use of the compounds of formula II in medical field, particularly in the preparation of medicaments for treating and preventing diabetes (in particular type II diabetes), hyperglycemia, X syndrome, hyperinsulinemia, obesity, atherosclerosis and all kinds of diseases modulated by immune system.
Abstract:
The present invention provides a method for disrupting pollen development in a plant, the method comprising inhibiting the expression of an endogenous nucleic acid molecule which is, under normal conditions, detectably expressed in anther tissue of a plant during pollen formation, and which codes for a protein belonging to the MYB class of DNA binding transcription factors. Particularly, the nucleic acid molecule whose expression is blocked encodes MYB 32 or MYB 103. The invention also provides nucleic acid molecules for use in the method, use of the method in producing male sterile plants and transgenic plants produced in accordance with the method.
Abstract:
The present invention relates to substituted pyridazinylamine derivatives of the formula I or pharmaceutically acceptable salts or hydrates thereof, wherein the substituents are defined as in the description, their preparation process, pharmaceutical compositions comprising them, and uses of the said compounds as picorna virus inhibitors for prevention and/or treatment of diseases caused by picorna viruses.
Abstract:
The present invention provides an expression cassette comprising a functional anther specific promoter nucleic acid molecule, homologous to the Ta39 promoter of tobacco, as well as functional homologues, orthologues and fragments of said functional anther specific promoter nucleic acid molecule. Also contemplated, are recombinant plasmids, plant cells and cell lines, transgenic plants and propagating material comprising the functional anther specific promoter nucleic acid molecule.
Abstract:
The present invention relates to arene connected polyamine macrocyclic derivatives represented by general formula I, pharmaceutically acceptable salts or hydrates thereof which have anti-HIV activities, in which the definitions of substituents are as defined in the description; to preparation methods of the compounds of formula I; to pharmaceutical compositions containing the compounds of formula I or their pharmaceutically acceptable salts or hydrates; to the use of the compounds of formula I or their pharmaceutically acceptable salts or hydrates for the preparation of a medicament for the treatment and prevention of HIV-associated diseases.
Abstract:
Vascular smooth muscle cells (VSMCs) adhere to and orient along micropatterned grooves having a depth of 1 to 10 μm and a width of 1 to 20 μm that are imposed on the surface of a vascular implant device. The VSMCs maintain an elongated morphology and reduced proliferation resulting in a decrease in occurrence of intimal hyperplasia upon device implantation.
Abstract:
The present invention relates to a compound of formula (I) or isomers thereof, or pharmaceutically acceptable salts or hydrates thereof. The present invention further relates to processes for the preparation of the compounds of formula (I) and optical isomers, and to the use of the compounds of formula (I), or isomers thereof, or pharmaceutically acceptable salts or hydrates thereof as medicaments, in particular as medicaments for the treatment and prevention of Hepatitis B.
Abstract:
The present invention relates to a compound of formula I, racemates, optically active isomers, or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutical composition comprising the compound, the various radicals in the formula I are the same as defined in the claims. The present invention also relates to a process for preparing the compound of formula I and use of said compound in the preparation of a medicament for the treatment of hyperglycemia, dyslipidemia, type II diabetes mellitus including associated diabetic dyslipidemia